Table 4.

CEP-701 inhibits engraftment of FLT3/ITD leukemia

Leukemia sample 1, % CD45, sorted		Leukemia sample 9, %CD45
		Sorted		Unsorted
Vehicle	CEP-701	Vehicle	CEP-701	Vehicle	CEP-701
3.3	0	96.1	8.7	98.3	50.4
3.2	0	89.0	74.6	94.2	19.1
4.7	0	95.5	13.2	92.6	76.9
4.6	0	95.6	91.2	75.7	11.7
11.3	0	95.0	86.9	98.0	46.5
19.4	0	90.2	80.0	90.0	—
9.3	0	94.7	1.3	—	—
—	0	95.3	78.2	—	—
8.0*	0*	93.9*	54.2*	91.5*	40.9*

CD34⁺/CD38⁻ cells (5 × 10³) obtained from leukemia sample 1 (Table 1) were injected via tail vein into 2 groups of 10 sublethally irradiated NOD-SCID mice. In a subsequent experiment, 5 × 10⁶ unsorted cells and 5 × 10³ CD34⁺/CD38⁻ cells from leukemia sample 9 were likewise injected into 4 groups of 8 mice. Mice were then treated with CEP-701 (20 mg/kg) or vehicle twice daily for 5 days every 4 weeks. Some of the mice in the different groups died of apparent infection in the first month of the experiment; thus, final numbers range from 5 to 8 for each group. At sacrifice, the bone marrow cells were analyzed by flow cytometry for human CD45 staining. The % CD45 refers to the percentage of the total marrow that stained for human CD45 (as compared with murine CD45).

—indicates the animal died.

^*Indicates the mean value for the mice in that group.